Skip to main content
main-content

05.11.2015 | Original Article | Ausgabe 4/2016 Open Access

Tumor Biology 4/2016

Chemotherapy promotes tumour cell hybridization in vivo

Zeitschrift:
Tumor Biology > Ausgabe 4/2016
Autoren:
Bingyu Yan, Jianguo Wang, Li Liu
Wichtige Hinweise

Electronic supplementary material

The online version of this article (doi:10.​1007/​s13277-015-4337-7) contains supplementary material, which is available to authorized users.

Highlights

We detect tumour cell fusion in vivo on mouse model.
Chemotherapy promotes tumour cell hybridization in vivo.

Abstract

Spontaneous cell-cell fusion has been recognized to be an important mechanism for tissue and organ development and repair. In cancer, cell fusion is critically involved in tumourigenesis, metastasis and drug resistance, as illustrated by in vitro experiments. However, there has been no direct detection of tumour cell fusion or hybridization in an in vivo tumour environment, and the features of hybridized cells under selective pressures, such as chemotherapy, are unknown. Here, we expressed two fluorescent marker proteins in the human breast cancer cell line SKBR3 to detect tumour cell hybridization in vivo and performed a xenograft chemotherapy experiment in mice to evaluate the chemotherapeutic response of the hybrids. The mice treated by epirubicin showed that chemotherapy promoted tumour cell hybridization in vivo, which elicited the production of more hybrids in the outer section of the tumour. These results provide the first in vivo evidence of tumour cell fusion and indicate that chemotherapy may contribute to a poor prognosis by enriching for fused cells, which are more malignant. It is therefore necessary to reassess chemotherapy strategies.

Unsere Produktempfehlungen

e.Med Interdisziplinär

Kombi-Abonnement

Mit e.Med Interdisziplinär erhalten Sie Zugang zu allen CME-Fortbildungen und Fachzeitschriften auf SpringerMedizin.de. Zusätzlich können Sie eine Zeitschrift Ihrer Wahl in gedruckter Form beziehen – ohne Aufpreis.

e.Med Onkologie

Kombi-Abonnement

Mit e.Med Onkologie erhalten Sie Zugang zu CME-Fortbildungen des Fachgebietes Onkologie, den Premium-Inhalten der onkologischen Fachzeitschriften, inklusive einer gedruckten onkologischen Zeitschrift Ihrer Wahl.

Zusatzmaterial
Figure S1 Control gates for FACS. a. Gate B: SKBR3 cells expressing no fluorescent proteins (negative control gate). b. Gate C: SKBR3 cells only expressing EGFP (EGFP control gate). c. Gate A: SKBR3 cells only expressing mCherry (mCherry control gate). d. Gate P: SKBR3 cells expressing both EGFP and mCherry in each cell (positive control gate). e. A mixture of SKBR3 cells expressing no fluorescent protein, EGFP or mCherry. These data were used to calculate the false positive rate. f. A mixture of SKBR3 cells expressing no fluorescent protein, EGFP, mCherry or both EGFP and mCherry. These data were used to calculate the discrimination ability of FACS. (PDF 1136 kb)
13277_2015_4337_MOESM1_ESM.pdf
Table S1 (PDF 64 kb)
13277_2015_4337_MOESM2_ESM.pdf
Literatur
Über diesen Artikel

Weitere Artikel der Ausgabe 4/2016

Tumor Biology 4/2016Zur Ausgabe